VSIG4 and breast carcinoma: In addition, the amount of CD274 showed no obvious increase in some cancers when compared with counterparts from healthy donors, especially those in PDAC, breast cancer, and ovarian cancer (Fig. 1B), indicating VSIG4+ TAMs is an unignorable subpopulation in the TME.